New drug combo aims to control High-Risk bladder cancer without prior treatment
NCT ID NCT05943106
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This study tests a combination of two drugs—BCG (a standard immunotherapy for bladder cancer) and durvalumab (an immune-boosting drug)—in adults with high-risk non-muscle-invasive bladder cancer who have not received BCG before. The goal is to see if the combination is safe and effective at controlling the cancer. About 100 participants across the U.S. will receive the treatment as an induction course followed by maintenance doses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON MUSCLE INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Phoenix, Arizona, 85054, United States
-
Research Site
Little Rock, Arkansas, 72211, United States
-
Research Site
San Diego, California, 92123, United States
-
Research Site
Lakewood, Colorado, 80228, United States
-
Research Site
Hialeah, Florida, 33016, United States
-
Research Site
Jacksonville, Florida, 32209, United States
-
Research Site
Greenwood, Indiana, 46143, United States
-
Research Site
Wichita, Kansas, 67226, United States
-
Research Site
Baltimore, Maryland, 21203, United States
-
Research Site
Hanover, Maryland, 21076, United States
-
Research Site
Royal Oak, Michigan, 48073, United States
-
Research Site
Troy, Michigan, 48084, United States
-
Research Site
Syracuse, New York, 13210, United States
-
Research Site
Cincinnati, Ohio, 45212, United States
-
Research Site
Bala-Cynwyd, Pennsylvania, 19004-1017, United States
-
Research Site
Myrtle Beach, South Carolina, 29572, United States
-
Research Site
Nashville, Tennessee, 37209, United States
-
Research Site
Austin, Texas, 78759, United States
-
Research Site
Spokane, Washington, 99202, United States
Conditions
Explore the condition pages connected to this study.